ArticleAnnals of medicine and surgery (2012)2025
Categorization of rheumatoid arthritis into mild, moderate, and severe conditions to discriminate specificity and sensitivity of routine diagnostic serum biomarkers.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Human biomarker navigator.iMeta · 2026Review
- Erratum: Categorization of rheumatoid arthritis into mild, moderate, and severe conditions to discriminate specificity and sensitivity of routine diagnostic serum biomarkers: erratum.Annals of medicine and surgery (2012) · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rheumatoid arthritis (RA) diagnosis continues to face challenges regarding the specificity and sensitivity of routine serological markers. This study aimed to assess the demographic distribution and serum biomarker profiles of RA patients with varying disease severity in Haryana, India, and to evaluate their diagnostic utility. Methods: A total of 200 participants were enrolled, including 150 RA patients and 50 healthy controls. RA patients were stratified into mild ( Results: Female predominance was observed across all RA severity groups, with the highest proportion in the severe category. Biomarker levels (RF, anti-CCP, and CRP) showed significant progressive elevation from mild to severe RA. Statistical analysis demonstrated robust correlations between biomarker titers and disease severity, with anti-CCP exhibiting the highest specificity among individual markers. Combined RF and anti-CCP assessment improved diagnostic accuracy. Chi-square tests revealed significant associations between biomarker profiles and disease severity, supporting their diagnostic relevance. Conclusions: Our findings underscore the clinical significance of combining serological biomarkers to enhance diagnostic precision in RA. The graded increase in biomarker titers across severity levels suggests their potential role in disease stratification and the development of tailored therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.